Last updated: March 26, 2026
What is the Drug Identified by NDC 46122-0775?
NDC 46122-0775 corresponds to Duloxetine hydrochloride capsules, 30 mg. Marketed under the brand name Cymbalta, it is primarily approved for depression, anxiety, diabetic peripheral neuropathy, and fibromyalgia.
Market Overview
Therapeutic Area and Indications
- Major Uses: Major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathy, fibromyalgia.
- Market Penetration: As of 2022, Cymbalta holds a significant share within the antidepressant market, though its dominance is challenged by newer classes such as SNRIs and atypical antidepressants.
Competitive Landscape
| Competitors |
Key Brands |
Indications |
Market Share (2022) |
| Sertraline (Zoloft) |
Pfizer |
MDD, GAD, PTSD |
15% |
| Escitalopram (Lexapro) |
Lundbeck/Forest |
MDD, GAD |
12% |
| Venlafaxine (Effexor) |
Pfizer |
MDD, GAD, neuropathy |
10% |
| Duloxetine (Cymbalta) |
Lilly |
MDD, GAD, neuropathic pain, fibromyalgia |
22% (market leader) |
Manufacturing & Supply Dynamics
- Lilly manufactures Cymbalta; production has aligned with global demand.
- Patent expiration in markets like the U.S. occurred in 2013, leading to increased generic availability.
- Generic versions significantly decreased the drug’s market value and shifted sales towards generics.
Price Trends and Projections
Current Pricing Landscape
| Product Type |
Price (Average Wholesale Price per 30 mg capsule) |
Notes |
| Brand (Cymbalta) |
$4.50 - $6.00 |
Relies on brand exclusivity; higher margins |
| Generic (Duloxetine) |
$0.10 - $0.50 |
Widely available post-patent expiration |
Price Drivers
- Patent Status: The U.S. patent expired in 2013, facilitating generic entry.
- Market Competition: Increased generics placed downward pressure on prices.
- Manufacturing Costs: Margins have compressed due to pricing erosion.
- Regulatory Policies: Some regions implement price controls affecting generics.
Forecasting Future Prices (Next 5 Years)
| Scenario |
Price per Capsule (30 mg) |
Rationale |
| Conservative (no new indications, high generic competition) |
$0.10 - $0.20 |
Market stabilized around lowest generic prices; minimal brand uptake |
| Moderate (new formulations or delivery methods) |
$0.20 - $0.35 |
Slight price increases due to improved formulations or market differentiation |
| Optimistic (new patents or indications) |
$3.00 - $4.00 |
Potential market exclusivity or licensed indications with limited generic competition |
Influencing Factors
- Patent Litigation and Market Exclusivity: New formulations or delivery systems could extend patent life, temporarily halting generics.
- Regulation and Reimbursement Policies: Price controls and formulary restrictions may suppress prices.
- Emergence of New Therapies: New drugs targeting the same indications could reduce demand for duloxetine.
Future Market Opportunities and Risks
Opportunities
- Development of sustained-release formulations to command higher prices.
- Repurposing for additional indications.
- Geographic expansion into emerging markets with less generic penetration.
Risks
- Price erosion due to increased generic competition.
- Regulatory delays in approval of new formulations.
- Competition from other neuromodulators, especially SNRIs and atypicals.
Key Takeaways
- Market share dominance: Cymbalta (duloxetine) remains a leading SNRI in its core indications, though generics dominate pricing.
- Pricing dynamics: Average wholesale prices for brand formulations declined sharply post-patent expiry, stabilizing at low levels.
- Price projections: Future revenues hinge on patent protections, new indications, and formulations; generic prices are expected to remain low.
- Market risks: Competition, regulatory policies, and market saturation limit upside potential.
FAQs
What are the primary factors affecting duloxetine pricing?
Patent status, generic competition, regulatory policies, and formulation innovations shape pricing patterns.
How does patent expiration impact the drug's market value?
Patent expiration enables generics, leading to price reductions and market share shifts toward lower-cost alternatives.
Are there opportunities for brand-name pricing increases?
Yes, through new formulations, delivery methods, or additional indications that justify premium pricing.
What regions present growth prospects?
Emerging markets with less generic penetration and lower healthcare costs could support increased sales.
How will competition influence future sales?
As more generics enter and existing brand rivals refine their offerings, market share and pricing for duloxetine are likely to decline unless new value propositions emerge.
Sources
[1] U.S. Food and Drug Administration. (2022). "Duloxetine Hydrochloride Capsules, 30 mg." Retrieved from FDA database.
[2] IQVIA. (2022). "Pharmaceutical Market Analysis."
[3] Evaluate Pharma. (2022). "Global Economics of Prescription Drugs."
[4] U.S. Patent and Trademark Office. (2013). "Patent expiry details for Cymbalta."
